Skip to content
Stocks News
Enter Ticker Symbol
  • Home
  • FEATURED COMPANY
  • ANALYST COVERAGE
  • NEWS
  • SUBSCRIBE
  • CONTACT

ANALYST COVERAGE

how-index-removals-and-fresh-analyst-coverage-will-impact-red-rock-resorts-(rrr)-investors

How Index Removals and Fresh Analyst Coverage Will Impact Red Rock Resorts (RRR) Investors

Jul 7, 2026

In late June 2026, Red Rock Resorts, Inc. was removed from several Russell value and small-cap indices, while…

Read more
analysts-see-more-upside-for-spacex-as-post-ipo-research-begins

Analysts see more upside for SpaceX as post-IPO research begins

Jul 7, 2026

Major brokerages initiated coverage on Tuesday with mostly buy ratings following the company’s $75 billion June IPO. (Tomas…

Read more
eli-lilly-stock-(lly)-opinions-on-medicare-coverage-and-drug-pipeline-advancements

Eli Lilly Stock (LLY) Opinions on Medicare Coverage and Drug Pipeline Advancements

Jul 7, 2026

By: Quiver DiscussionTracker Posted: 1 day, 22 hours ago / July 5, 2026 5:33 p.m. UTC Medicare Expansion Impact: Social…

Read more
spacex-joins-nasdaq-100-riding-a-wave-of-buy-ratings

SpaceX Joins Nasdaq 100 Riding A Wave Of Buy Ratings

Jul 7, 2026

Access to this page has been denied because we believe you are using automation tools to browse the…

Read more
deutsche-bank-initiates-spacex-stock-coverage-with-buy-rating

Deutsche Bank initiates SpaceX stock coverage with buy rating

Jul 7, 2026

Deutsche Bank initiates SpaceX stock coverage with buy rating

Read more
citi-initiates-spacex-stock-coverage-with-buy-rating,-$200-target

Citi initiates SpaceX stock coverage with buy rating, $200 target

Jul 7, 2026

Citi initiates SpaceX stock coverage with buy rating, $200 target

Read more
here-are-tuesday’s-best-wall-street-analyst-research-calls:-adobe,-american-airlines,-broadcom,-first-solar,-meta-platforms,-shopify,-space-x,-ventas,-waste-managment,-and-more

Here Are Tuesday’s Best Wall Street Analyst Research Calls: Adobe, American Airlines, Broadcom, First Solar, Meta Platforms, Shopify, Space-X, Ventas, Waste Managment, and More

Jul 7, 2026

Pre-Market Stock Futures: Futures are trading mixed, with the Nasdaq getting hammered after a gangbuster start to the…

Read more
this-performance-food-group-analyst-begins-coverage-on-a-bullish-note;-here-are-top-5-initiations-for-tue

This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tue

Jul 7, 2026

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…

Read more
analysts-bullish-on-apotex-as-they-initiate-coverage-following-canadian-drugmaker’s-ipo

Analysts bullish on Apotex as they initiate coverage following Canadian drugmaker’s IPO

Jul 7, 2026

Empty pill bottles are filled with Apo-Clonidine, an antihypertensive or vascular stabilizer, at the Apotex Health Corp. plant…

Read more
morgan-stanley-analyst-initiates-spacex-coverage,-sees-nearly-90%-upside-for-elon-musk’s-spcx

Morgan Stanley Analyst Initiates SpaceX Coverage, Sees Nearly 90% Upside for Elon Musk’s SPCX

Jul 7, 2026

Adam Jonas Bullish on SpaceX In a new note released on Monday, Jonas predicted a bull case of…

Read more
abivax-sa-(abvx)-uc-opportunity:-oral-therapy-catalyst

Abivax SA (ABVX) UC Opportunity: Oral Therapy Catalyst

Jul 7, 2026

Abivax SA (ABVX) advances obefazimod through Phase 3 success in ulcerative colitis with NDA filing targeted for late…

Read more
french-clinical-stage-biotech’s-uc-drug-faces-‘best-in-disease’-doubts-as-analyst-lifts-target-ahead-of-4q26-fda-filing

French Clinical-Stage Biotech’s UC Drug Faces ‘Best in Disease’ Doubts as Analyst Lifts Target Ahead of 4Q26 FDA Filing

Jul 7, 2026

A Wedbush analyst raised its target on a French biopharma’s ulcerative colitis candidate but disputed bullish efficacy claims,…

Read more
  1. Pages:
  2. «
  3. 1
  4. 2
  5. 3
  6. 4
  7. 5
  8. 6
  9. 7
  10. 8
  11. ...
  12. 445
  13. »

Posts pagination

Newer posts Page 1 … Page 5 … Page 445 Older posts

The content presented on this site is intended solely for entertainment purposes and should not be construed as an invitation to engage in the purchase or sale of securities. Each content provider featured on 10x Wealth Report brings a unique perspective and predisposition, which may not necessarily align with that of 10x Wealth Report. It is crucial to recognize that 10x Wealth Report is not a registered financial advisor or firm. Read More full disclaimer

CATEGORIES

  • FEATURED COMPANY
  • NEWS
  • ANALYST COVERAGE
  • Special Post
  • CONTACT
  • SUBSCRIBE
  • Privacy Policy
  • Terms or Service
  • Disclaimer

CONNECT & FOLLOW

© 10x Wealth Report Copyright 2024.